Maximon

Maximon empowers entrepreneurs to build impactful and science-based companies providing healthy aging and rejuvenation solutions in the field of longevity.

[Maximon @maximon_ag]

https://t.co/Mv9TEE5M6V

[Maximon @maximon_ag]

𝐖𝐡𝐚𝐭 𝐝𝐨𝐞𝐬 𝐢𝐭 𝐭𝐚𝐤𝐞 𝐭𝐨 𝐛𝐮𝐢𝐥𝐝 𝐢𝐧 𝐚 𝐟𝐢𝐞𝐥𝐝 𝐛𝐞𝐟𝐨𝐫𝐞 𝐭𝐡𝐞 𝐦𝐚𝐫𝐤𝐞𝐭 𝐟𝐮𝐥𝐥𝐲 𝐞𝐱𝐢𝐬𝐭𝐬?

In a recent interview with Unfiltered Marc P. Bernegger shared why longevity may become one of the next major technological frontiers.

[Longevity Investors @Longevity_Inv]

Two features. One conversation the longevity industry can't avoid.
Moneycab has published an in-depth interview with our CEO, Lucia Kupcova, alongside a look at the LIC 2026 programme.
All our coverage: https://t.co/C22mhKHFUK

#LongevityInvestors #LIC2026

[Maximon @maximon_ag]

𝐌𝐚𝐱𝐢𝐦𝐨𝐧 𝐚𝐭 𝐛𝐢𝐨:𝐜𝐚𝐩 2026 𝐢𝐧 𝐁𝐞𝐫𝐥𝐢𝐧

From 09–11 June 2026, bio:cap will bring together leaders from life sciences, AI, biotech, diagnostics and investment at CityCube Messe Berlin.
Our Founding Partner Marc P. Bernegger will be joining a panel discussion.

[Longevity Investors @Longevity_Inv]

The longevity funding leaderboard has changed.Altos Labs anchors at $5.56B. Retro Biosciences moved from $180M to $1.18B+ at $1.8B. Insilico Medicine completed the largest HK biotech IPO of the year, with Eli Lilly and Tencent as cornerstones. @newlimit : direct Lilly equity at $1.62B. @Oura ($11B), @function ($2.5B), Neko Health ($1.8B) entered the top ten.

Full analysis: https://t.co/dxXxbwCd6H #LIC2026

[Maximon @maximon_ag]

Longevity as a Business: Can You Scale Health?
Maximon’s Co-Founder Marc P. Bernegger will join the stage at Life Summit Berlin for a panel discussion on one of the most relevant questions in longevity today.
At Maximon, we believe longevity is not only about breakthrough science

[Longevity Investors @Longevity_Inv]

What if the science and the capital finally spoke the same language?

@bulletproofexec. @aubreydegrey. @prof_horvath. @NirBarzilaiMD. Adeel Khan. @CollinEwald. @M_S_Ringel.
30+ speakers. 1 for every 4 attendees.

LIC 2026. Gstaad. Application-only.
Early Bird closes 31 May: https://t.co/OxSniE46yJ
#LIC2026

[Maximon @maximon_ag]

@BusinessInsider has released its 1st-ever Rising Stars of Longevity list,highlighting 11 leaders who are helping shape the future of healthy aging across medicine,AI,biotech,and investment. @marcpbernegger, Founder of Maximon, was part of the panel helping evaluate the finalists

[Longevity Investors @Longevity_Inv]

The longevity market hits $8T by 2030. Surpassing AI.
@JeffBezos put $3B into @altos_labs Labs. Altman $180M into @RetroBio_ . Armstrong co-founded @newlimit at $5B valuation. Longevity investment doubled in one year.
Family offices are building this economy. Not just funding it.

LINews 👇 https://t.co/QkqSd5WCyq

[Longevity Technology @LongevityTech]

The immune system gets a digital twin, bringing predictive, personalized modeling into the core of longevity medicine.
ㅤ
Link in bio.
ㅤ
#longevity #ai #healthspan #immunology #innovation

[Bernegger Ventures @BernVen]

Bitcoin e longevità, due rivoluzioni parallele

L'imprenditore svizzero Marc Bernegger ha tracciato un parallelo tra la sfida di Bitcoin all'inflazione e quella della scienza all’invecchiamento

https://t.co/biEMEojnn4

via @Ticinonline at @LuganoPlanB with @marcpbernegger

[Digital Finance Forum @DigitalFinForum]

We are pleased to announce @marcpbernegger , Founder & Chairman of @Longevity_Inv, as a speaker at the Bermuda Digital Finance Forum 2026!

Learn more and register: https://t.co/ukr8mMfALT

[Maximon @maximon_ag]

Dr. Tobias Reichmuth , Founding Partner at Maximon, has been named Founder of the Year 2026 by University of St.Gallen 🏆

The award was presented at START Summit in St. Gallen and recognises Tobias as a serial entrepreneur and investor who has helped build companies across climate finance, crypto and, more recently, longevity.
For us at Maximon, this recognition is especially meaningful because it highlights a mission we deeply believe in: turning cutting-edge science into real-world solutions that help people stay healthier for longer.
Through Maximon, Tobias has helped build ventures such as AVEA, AYUN and Frieda Health, all part of a broader effort to advance prevention, personalised health and healthy aging. Maximon’s mission is to empower entrepreneurs to build impactful, science-based and scalable companies in healthy aging and rejuvenation.
Congratulations, Tobias, on this well-deserved recognition. 👏

[Maximon @maximon_ag]

https://t.co/VjdP5IBpH4

[Maximon @maximon_ag]

Is aging a disease or a natural process we can meaningfully influence?⏳

In SRF - Schweizer Radio und Fernsehen’s 𝘚𝘵𝘦𝘳𝘯𝘴𝘵𝘶𝘯𝘥𝘦 𝘗𝘩𝘪𝘭𝘰𝘴𝘰𝘱𝘩𝘪𝘦 𝘦𝘱𝘪𝘴𝘰𝘥𝘦 “𝘐𝘴𝘵 𝘈𝘭𝘵𝘦𝘳𝘯 𝘦𝘪𝘯𝘦 𝘒𝘳𝘢𝘯𝘬𝘩𝘦𝘪𝘵? Ü𝘣𝘦𝘳 𝘥𝘦𝘯 𝘛𝘳𝘢𝘶𝘮 𝘷𝘰𝘮 𝘭𝘢𝘯𝘨𝘦𝘯 𝘓𝘦𝘣𝘦𝘯”, Dr. Tobias Reichmuth joins Thomas Schulz (DER SPIEGEL) for a thoughtful follow-up conversation sparked by the recent SRF longevity documentary.

The interview goes beyond “biohacking headlines” and into the real questions the longevity movement has to answer:
• Where does prevention end and “optimization” begin?
• What’s scientifically realistic today and what still belongs in the future?
• How do we ensure longer lives translate into better lives (for individuals and for society)?

The conversation quickly shifts 𝐟𝐫𝐨𝐦 𝐭𝐡𝐞𝐨𝐫𝐲 𝐭𝐨 𝐬𝐨𝐦𝐞𝐭𝐡𝐢𝐧𝐠 𝐦𝐨𝐫𝐞 𝐩𝐞𝐫𝐬𝐨𝐧𝐚𝐥. Tobias shares his own perspective on longevity and a point we strongly agree with: there is 𝐧𝐨 𝐨𝐧𝐞-𝐬𝐢𝐳𝐞-𝐟𝐢𝐭𝐬-𝐚𝐥𝐥 𝐛𝐥𝐮𝐞𝐩𝐫𝐢𝐧𝐭.
What works for one person’s biology, lifestyle, and goals may not work for another’s. Longevity isn’t just a trend, it’s an individual journey shaped by context, genetics, behaviors, and priorities.

That’s also why measurement and personalization matter and we're proud to back AYUN Clinic, where longevity is approached through data-driven diagnostics and tailored longevity check-ups and programs, helping people understand their current health status and make informed, realistic changes based on their markers and needs.

⬇️ Watch the discussion (🔗in comments) and share your view!

[Maximon @maximon_ag]

https://t.co/db5dv07hEe

[Maximon @maximon_ag]

📺 Longevity is moving from niche to mainstream and Swiss public TV is asking the right questions.

SRF - Schweizer Radio und Fernsehen just released the documentary “Longevity – Auf der Suche nach einem erfüllten Leben”, following Mona Vetsch and Yves Bossart on a nearly year-long experiment to rethink daily habits, track key health metrics, and explore what it means to live longer and better.

What makes it compelling is that it doesn’t reduce longevity to numbers alone. It connects the science with the very human question of what a 𝐟𝐮𝐥𝐟𝐢𝐥𝐥𝐞𝐝 𝐥𝐢𝐟𝐞 looks like.
The film also offers great impressions from their two-day visit to the Longevity Investors Conference (LIC), a reminder that longevity is no longer just a research topic, but an ecosystem where science, entrepreneurship, and capital are converging to accelerate real-world progress.

We also appreciated seeing AYUN Clinic featured. AYUN stands for a proactive, data-driven approach to healthspan, combining advanced diagnostics with medical expertise and practical, personalized guidance. In the episode, assessments and tests were carried out by Dr. Dr. med. Oliver Boekels, Lead Physician at AYUN, helping translate complex biomarkers into clear next steps people can act on.

At Maximon, we build and back ventures that bring longevity science into real-world impact, with one clear focus: extend healthspan, not just lifespan.
Watch the whole coverage (🔗 in comments).

[Maximon @maximon_ag]

https://t.co/IkC2JeG2Bv

[Maximon @maximon_ag]

Building longevity isn’t just a lab story, it’s also a story of capital, conviction, and the big questions society needs to debate.

Swiss national TV, Radiotelevisione Svizzera (RSI) just covered the longevity space in Falò’s episode “𝘝𝘪𝘷𝘦𝘳𝘦 𝘧𝘪𝘯𝘰 𝘢 140 𝘢𝘯𝘯𝘪?” and it features Marc P. Bernegger and the Longevity Investors community.

The episode dives into what’s driving the global race for longer healthspans:
• why billions are flowing into longevity R&D
• what’s real science vs. hype
• and what it could mean if living to 120+ becomes more than a thought experiment

At Maximon, we build and back ventures that turn breakthrough science into real-world impact, responsibly, and with a long-term mindset.
If you’re curious to see how mainstream this topic has become, watch the segment (🔗 link in comments)

[Maximon @maximon_ag]

https://t.co/F1kjXRVgMG

[Maximon @maximon_ag]

Maximon's Founding Partners Dr. Tobias Reichmuth and Marc P. Bernegger were featured in https://t.co/ios4sdK13B in connection with the Longevity Investors Lunch in Davos, where longevity science meets capital.

Beyond attending, Tobias and Marc are also the 𝐟𝐨𝐮𝐧𝐝𝐞𝐫𝐬 𝐚𝐧𝐝 𝐡𝐨𝐬𝐭𝐬 𝐛𝐞𝐡𝐢𝐧𝐝 𝐋𝐨𝐧𝐠𝐞𝐯𝐢𝐭𝐲 𝐈𝐧𝐯𝐞𝐬𝐭𝐨𝐫𝐬 𝐚𝐧𝐝 𝐢𝐭𝐬 𝐞𝐯𝐞𝐧𝐭𝐬, convening builders, researchers and investors to advance the healthspan agenda forward, grounded in science, and focused on real-world impact.

Some of the strongest themes highlighted:

• 𝐔𝐥𝐭𝐫𝐚-𝐩𝐞𝐫𝐬𝐨𝐧𝐚𝐥𝐢𝐳𝐞𝐝 𝐦𝐞𝐝𝐢𝐜𝐢𝐧𝐞: shifting from “average humans” to individual biology
• 𝐂𝐚𝐩𝐢𝐭𝐚𝐥 𝐛𝐮𝐢𝐥𝐝𝐢𝐧𝐠 𝐡𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐢𝐧𝐟𝐫𝐚𝐬𝐭𝐫𝐮𝐜𝐭𝐮𝐫𝐞: from concierge care to integrated ecosystems
• 𝐌𝐞𝐝𝐢𝐜𝐢𝐧𝐞 3.0 𝐚𝐧𝐝 𝐀𝐈-𝐞𝐧𝐚𝐛𝐥𝐞𝐝 𝐩𝐫𝐞𝐯𝐞𝐧𝐭𝐢𝐨𝐧: moving from reactive care to proactive optimisation
A needed reminder to stay evidence-based, including caution around 𝐰𝐞𝐥𝐥𝐧𝐞𝐬𝐬 𝐈𝐕𝐬 and questionable supplementation

Tobias and Marc also delivered the 𝐜𝐥𝐨𝐬𝐢𝐧𝐠 𝐬𝐩𝐞𝐞𝐜𝐡, reflecting on what it takes to turn frontier science into scalable healthspan outcomes.

🔗 We’ll share the article and event background links in the comments.